In order to reconfirm the optimal dose and search for the clinical benefits of biapenem (BIPM), a parenteral carbapenem antibiotic, in the treatment of acute exacerbation of chronic bronchitis, a randomized, three- group comparative study against imipenem/cilastatin (IPM/CS) as a comparator was performed by using a telephone registration method, and the following results were obtained. BIPM at 300 (group L) or 600 (group H) mg/day in two- divided doses and IPM/CS at 1,000 mg/1,000 mg/day (group C) in two-divided doses were systemically administered. The duration of treatment was within 14 days. The number of patients evaluated for clinical efficacy out of the total 35 patients registered was 32 cases (L group 10 cases, H group 10 cases, C group 12 cases). 1) Clinical effects: The efficacy rates were 100% (10/10), 90.0% (9/10), and 91.7% (11/12) in group L, H, and C, respectively. For the evaluation of early onset after 3 days of treatment, the efficacy rates were 60.0% (6/10), 90.0% (9/10), and 58.3% (7/12) in group L, H, and C, respectively. 2) Bacteriological effects: The bacterial eradication rates were 100% (6/6), 100% (3/3), and 100% (9/9) in groups L, H, and C, respectively. 3) Side effects were observed at a rate of 8.3% (1/12) in group C. The severity of the drug fever/drug eruption was moderate. No side effects were observed in group L and H. 4) Abnormal laboratory findings were observed at a rate of 20% (2/10) in group L, 33.3% (4/12) in group H, and 20% (2/10) in group C. These abnormal findings were mild. 5) Usefulness: The usefulness rates were 100% (10/10), 90% (9/10), and 83.3% (10/12) in groups L, H, and C, respectively. There were no statistical differences in every evaluation among the 3 groups. The rate of efficacy on day 3 that reflects the early response of the drug treatment is 600 mg a day and the highest efficacy rate. These results demonstrated that the 600 mg a day was the appropriate clinical dosage of BIPM with an early clinical effect in the treatment of chronic bronchitis from the point of view of efficacy and safety.
|Number of pages||11|
|Journal||Japanese Journal of Chemotherapy|
|Publication status||Published - 2000|
ASJC Scopus subject areas
- Pharmacology (medical)